The Center for Breakthrough Medicines announced a partnership with London-based Achilles Therapeutics plc. The deal provides expanded cell therapy manufacturing capabilities required to supply products for Achilles' ongoing Phase I/IIa clinical trials in advanced non-small cell lung cancer and metastatic or recurrent melanoma patients. CBM is a contract development and manufacturing organization (CDMO) dedicated to addressing the challenges associated with developing and manufacturing advanced therapies.

Achilles is a clinical-stage biopharmaceutical company developing precision T-cell therapies to treat solid tumors. CBM will manufacture Achilles' precision T cell therapy for the company's ongoing Phase I/IIa clinical trials in non-small cell lung cancer and melanoma patients.